Successful therapy of metastatic breast cancer with surgery, NST, DLI, and autologous tumor cell vaccines.
(A) Experimental scheme. (B) BALB/c mice received 104 4T1 cells subcutaneously on day 0. The subcutaneous tumor was resected on day 13, prior to NST from syngeneic BALB/c or MHC-compatible B10.D2 donors. NST consisted of 200 cGy TBI on day 13, 10 million donor marrow cells intravenously on day 14, and cyclophosphamide 200 mg/kg intraperitoneally on day 17. Mice receiving B10.D2 marrow then received nothing (○), 20 million B10.D2 splenocytes on day 28 (▾), autologous tumor vaccine on day 31 (▿; 106 irradiated autologous tumor cells mixed with 5 × 105 B78H1/GM-CSF, a GM-CSF–secreting, MHC-negative bystander cell line), or 20 million B10.D2 splenocytes plus vaccine (▪). Mice receiving BALB/c marrow also received 20 million BALB/c splenocytes plus vaccine (■). An additional group of BALB/c mice received 4T1 subcutaneously on day 0 and surgery on day 13 without further therapy (●). Tumor-free survival is plotted as a function of time after subcutaneous tumor inoculation. This experiment has been repeated twice, but without syngeneic NST controls, with similar results.
